Clinical Trial · NCT05820724

PSMA PET Scan and mpMRI for Prostate Cancer Detection

Overview

Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate cancer as compared to mpMRI alone.

Sponsor

VA Greater Los Angeles Healthcare System

Phase

Phase 2

Contacts

William Aronson, MD (PRINCIPAL_INVESTIGATOR)

William Aronson, MD (CONTACT)

william.aronson@va.gov

310-268-3446

ClinicalTrials.gov

NCT05820724

Drug / Compound

DCFPyL

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

Patients with PI-RADS 4-5 lesion(s) on mpMRI and have elected to undergo a prostate biopsy
Patient willing to be randomized to prostate mpMRI only vs prostate mpMRI + DCFPyL PET/CT
Prostate mpMRI completed within 9 months prior to enrollment

Exclusion

Medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study procedures or compliance.
Creatinine clearance exceeding institutional requirements for prostate mpMRI